AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%
Baker Hughes Company
BKR Details
Baker Hughes Company (NYSE: BKR) is an energy technology company that provides a wide range of products and services to consumers in the energy and industrial value chains. Its operating segments are 1) Oilfield Services (OFS), 2) Oilfield Equipment (OFE), 3) Turbomachinery & Process Solutions (TPS), and 4) Digital Solutions (DS). With operations in over 120 countries, it principally provides products and services in the upstream, middle, and downstream sections of the oil and gas sector. As of January 12, 2022, the company's market capitalization stood at USD 28.11 billion.
Latest News:
Q3FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/EBITDA Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
BKR Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
BKR's stock price has increased 31.35% in the past nine months and is currently leaning towards the higher band of its 52-week range of USD 18.75 to USD 27.66. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is at 66.61. We have valued the stock using the EV/EBITDA multiple-based relative valuation methodology and arrived at a target price of USD 24.49.
Considering the uptick in the stock price, technical indicators, and current valuation, we believe the decent business fundamentals are adequately reflected at current trading levels. Hence, we recommend a "Sell" rating on the stock at the closing price of USD 26.73, down 0.85%, as of January 12, 2022.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Sage Therapeutics, Inc.
SAGE Details
Sage Therapeutics, Inc. (NASDAQ: SAGE) is a biopharmaceutical company that develops and markets therapies to treat illnesses of the central nervous system. It generates revenue by selling ZULRESSO (brexanolone), an injectable used to treat postpartum depression (PPD). It is also working on treating brain illnesses and disorders, specifically depression, neurology, and neuropsychiatry.
Latest News:
Previously on December 01, 2021, SAGE and Biogen announced positive one-year Zuranolone 50 mg data in Patients with MDD in the ongoing open-label SHORELINE study. Zuranolone 50 mg was generally well tolerated, with an overall adverse event profile comparable with previous data and a 6.5% discontinuation rate due to adverse events.
Q3FY21 Results:
Risks:
Outlook:
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
SAGE Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
SAGE's stock price increased 10.82% in the past month and is currently leaning towards the lower end of its 52-week range of USD 36.13 to USD 98.39. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 56.38. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 39.31.
Considering the uptick in the stock price, current valuation, and technical indicators, we believe the decent business fundamentals are adequately reflected at current trading levels. Hence, we recommend a "Sell" rating on the stock at the current price of USD 43.54, down 0.07%, as of January 12, 2022, at 12:57 PM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.